Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 3/20 | 1.00 |
| ▸ | CDC25B | P30305 | 3/20 | 1.00 |
| ▸ | BCHE | P06276 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 4/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosteviol SCHEMBL22922207 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL3489810 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL13401648 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL439433 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL2987296 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL14925190 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL2025230 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| Isosteviol SCHEMBL26990273 | 1.00 | F10 (1.00) | F10PTPN1PTPN2CDC25BBCHE | |
| SCHEMBL17066125 | 0.87 | F10 (0.77) | F10PTPN1PTPN2CDC25BBCHE | |
| SCHEMBL13242208 | 0.87 | F10 (0.77) | F10PTPN1PTPN2CDC25BBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | SORD, CASP3, TXNRD2 | F10 551/4885PTPN1 3492/4885PTPN2 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.